The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kurkin D.V.
Russian University of Medicine;
Volgograd State Medical University
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(5): 22‑30
Views: 1009
Downloaded: 2
To cite this article:
Kurkin DV, Morkovin EI, Bakulin DA, et al. . Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry.
2024;124(5):22‑30. (In Russ.)
https://doi.org/10.17116/jnevro202412405122
Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.
Authors:
Kurkin D.V.
Russian University of Medicine;
Volgograd State Medical University
Received:
21.12.2023
Accepted:
23.01.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.